Dr. Josh Jang has a Ph.D. in molecular genetics and genomics from Washington University in St. Louis and a B.S. in health promotion and disease prevention from University of Southern California. His graduate work focused on characterizing transposable elements’ contribution to oncogenic potential in cancer cell line models, as well as other projects that established and optimized targeted epigenetic technologies using CRISPR-Cas9 technology. In 2020, Dr. Jang joined Van Andel Institute as a VAI Fellow under Drs. Peter A. Jones and Stephen B. Baylin.